Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 06, 2022 08:00 ET | Source: Viridian Therapeutics, Inc.

Viridian Therapeutics to Participate in The 21st Annual Needham Virtual Healthcare Conference on April 14

WALTHAM, Mass., April 06, 2022 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company advancing new treatments for patients suffering from serious diseases...
April 04, 2022 16:05 ET | Source: Viridian Therapeutics, Inc.

Viridian Therapeutics Secures Flexible Credit Facility for Up to $75 Million From Hercules Capital

WALTHAM, Mass., April 04, 2022 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company advancing new treatments for patients suffering from serious diseases...
March 21, 2022 16:05 ET | Source: Viridian Therapeutics, Inc.

Viridian Therapeutics Doses First Subject in First-in-Human Clinical Trial Evaluating VRDN-002, a Next Generation IGF-1R Antibody for the Treatment of Thyroid Eye Disease

- VRDN-002 incorporates clinically validated half-life extension technology to support development as a low volume subcutaneous injection that could broaden settings of care - - Top line results from...
March 14, 2022 16:05 ET | Source: Viridian Therapeutics, Inc.

Viridian Therapeutics to Participate in 32nd Annual Oppenheimer Healthcare Conference on March 15

WALTHAM, Mass., March 14, 2022 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company advancing new treatments for patients suffering from serious diseases...
March 10, 2022 16:05 ET | Source: Viridian Therapeutics, Inc.

Viridian Therapeutics Reports Fourth Quarter And Full Year 2021 Financial Results And Provides Corporate Updates

-- Ongoing Phase 1/2 clinical trial for VRDN-001, an IGF-1R antibody for the treatment of Thyroid Eye Disease, is on track to report top line proof of concept data in the second quarter of 2022 -- ...
March 03, 2022 16:16 ET | Source: Viridian Therapeutics, Inc.

Viridian Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results and Host Investor Conference Call on March 10, 2022

WALTHAM, Mass., March 03, 2022 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company advancing new treatments for patients suffering from serious diseases...
February 14, 2022 08:00 ET | Source: Viridian Therapeutics, Inc.

Viridian Therapeutics to Participate in the SVB Leerink 2022 Global Healthcare Conference on February 18

WALTHAM, Mass., Feb. 14, 2022 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company advancing new treatments for patients suffering from serious diseases...
January 31, 2022 07:00 ET | Source: Viridian Therapeutics, Inc.

Viridian Therapeutics Announces FDA Clearance of Investigational New Drug Application to Initiate Clinical Development of VRDN-002, a Next Generation IGF-1R Antibody for the Treatment of Thyroid Eye Disease

- VRDN-002 incorporates clinically validated half-life extension technology to support development as a low volume subcutaneous injection -- Company expects to report top line VRDN-002 Phase 1...
January 04, 2022 07:00 ET | Source: Viridian Therapeutics, Inc.

Viridian Therapeutics Submits Investigational New Drug Application for VRDN-002 to the U.S. Food and Drug Administration

- VRDN-002 is a novel anti-IGF-1R monoclonal antibody for thyroid eye disease and incorporates half-life extension technology designed to improve dosing and administration - - Company...
December 20, 2021 07:00 ET | Source: Viridian Therapeutics, Inc.

Viridian Therapeutics Announces First Subject Dosed in Phase 1/2 Clinical Trial of VRDN-001 for Thyroid Eye Disease (TED)

- VRDN-001 targets and blocks IGF-1R, the only mechanism of action proven to deliver efficacy in TED -- Trial is on track to deliver top line proof of concept clinical data in 2Q 2022 - WALTHAM,...